Back
Compare AU
Compare HQUS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares S&P 500 Equal Weight Currency Hedged ETF (HQUS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HQUS | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 68 |
Median incremental investment | $4,993.50 | $665.63 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,331.52 | $1,841.81 |
Average age group | > 35 | > 35 |
Key Summary
HQUS | CURE | |
|---|---|---|
Strategy | HQUS.AX was created on 2024-07-10 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. HQUS.AX aims to track the performance of the S&P 500 Equal Weight AUD Hedged Index NTR. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 40.41m in AUM and 144 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BetaShares S&P 500 Equal Weight ETF (99.92 %) | Moderna Inc (2.31 %) Roivant Sciences Ltd Ordinary Shares (1.77 %) Arcellx Inc (1.75 %) |
Top 3 industries | Industrials (15.79 %) Financials (14.65 %) Information Technology (13.66 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (98.88 %) Switzerland (0.37 %) China (0.21 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.29 % | 0.45 % |
Key Summary
HQUS | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | S&P 500 Equal Weight AUD Hedged Index - AUD - Benchmark TR Net Hedged | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.29 % | 0.45 % |
Price | $46.08 | $58.47 |
Size | N/A | $40.390 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.68 % | 5.08 % |
Market | ASX | ASX |
First listed date | 11/07/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HQUS | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 11 | 68 |
Median incremental investment | $4,993.50 | $665.63 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,331.52 | $1,841.81 |
Average age group | > 35 | > 35 |
Pros and Cons
HQUS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HQUS | CURE |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |